Public Service Enterprise Group Aktie News

LIPA Board of Trustees awards PSEG Long Island extension of existing contract for five years continuing the successful partnership for the last 12 years. NEWARK, N.J.

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company announcement replaces company announcement no. 10 published on 1 September 2025.

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen, September 01, 2025 Company Announcement No. 10 Reponex Pharmaceuticals A/S (Reponex), a subsidiary of Pharma Equity Group A/S (NASDAQ: PEG), today announced that it has received regulatory approval to initiate a ...

I maintain my strong buy rating on PEG, driven by surging data center demand and a robust 2Q25 earnings beat. PEG's large-load inquiry pipeline soared to 9.4 GW, with ~90% tied to data centers, underscoring a powerful multi-year growth runway. Higher PJM auction clearing prices and nuclear fleet optimization initiatives significantly boost PEG's earnings visibility and de-risk future cash flows.

The world is having a “nuclear renaissance,” according to Morgan Stanley, and the opportunity for investors is ample.

Public Service (PEG) Q2 EPS Jumps 22%

Public Service Enterprise Group Incorporated (NYSE:PEG ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Carlotta N. Chan - Vice President of Investor Relations Daniel J.

$1.17 PER SHARE NET INCOME $0.77 PER SHARE NON-GAAP OPERATING EARNINGS Maintains 2025 Non-GAAP Operating Earnings Guidance of $3.94 - $4.06 Per Share NEWARK, N.J., Aug. 5, 2025 /PRNewswire/ -- Public Service Enterprise Group (NYSE: PEG) reported the following results for the second quarter and six months ended June 30, 2025: PSEG Consolidated (unaudited)Second Quarter Comparative Results Income...